{
    "Clinical Trial ID": "NCT00248170",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Letrozole",
        "  2.5 mg by mouth (p.o.) once daily",
        "INTERVENTION 2: ",
        "  Anastrozole",
        "  1 mg p.o. once daily"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Recent primary surgery for breast cancer",
        "  Early stage breast cancer",
        "  Postmenopausal",
        "  Hormone receptor positive",
        "  Positive lymph node involvement",
        "Exclusion Criteria:",
        "  Metastatic disease",
        "  Presence of contralateral breast cancer including DCIS",
        "  Progression",
        "  Other protocol-defined inclusion/exclusion criteria may apply."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Disease Free Survival",
        "  Disease-free survival was defined as the time from the date of randomization to the date of the first documentation of re-occurrence of invasive breast cancer in local, regional or distant sites, new invasive breast cancer in the contra-lateral breast, or death from any cause.",
        "  Time frame: 84 months",
        "Results 1: ",
        "  Arm/Group Title: Letrozole",
        "  Arm/Group Description: 2.5 mg by mouth (p.o.) once daily",
        "  Overall Number of Participants Analyzed: 2061",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: Months  NA  [1]    (84.14 to NA)",
        "Results 2: ",
        "  Arm/Group Title: Anastrozole",
        "  Arm/Group Description: 1 mg p.o. once daily",
        "  Overall Number of Participants Analyzed: 2075",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: Months  NA  [1]    (NA to NA)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 486/2049 (23.72%)",
        "  Anaemia 4/2049 (0.20%)",
        "  Autoimmune haemolytic anaemia 0/2049 (0.00%)",
        "  Haemorrhagic anaemia 1/2049 (0.05%)",
        "  Lymphadenopathy 0/2049 (0.00%)",
        "  Pancytopenia 0/2049 (0.00%)",
        "  Acute coronary syndrome 1/2049 (0.05%)",
        "  Acute myocardial infarction 3/2049 (0.15%)",
        "  Adams-Stokes syndrome 1/2049 (0.05%)",
        "  Angina pectoris 8/2049 (0.39%)",
        "  Angina unstable 1/2049 (0.05%)",
        "Adverse Events 2:",
        "  Total: 520/2062 (25.22%)",
        "  Anaemia 3/2062 (0.15%)",
        "  Autoimmune haemolytic anaemia 1/2062 (0.05%)",
        "  Haemorrhagic anaemia 0/2062 (0.00%)",
        "  Lymphadenopathy 2/2062 (0.10%)",
        "  Pancytopenia 1/2062 (0.05%)",
        "  Acute coronary syndrome 1/2062 (0.05%)",
        "  Acute myocardial infarction 4/2062 (0.19%)",
        "  Adams-Stokes syndrome 0/2062 (0.00%)",
        "  Angina pectoris 8/2062 (0.39%)",
        "  Angina unstable 2/2062 (0.10%)"
    ]
}